Weight changes in @entity164 2 XXXX and the impact of gender.

@entity1 @entity353 @entity6 @entity1017 @entity164 @entity2449
AIMS: Many studies suggest that @entity1017 occurs during treatment of @entity164 2 @entity6 , irrespective of the treatment @entity164 . The aim of this study was to address the questions (i) whether @entity1017 is inevitable in @entity1 treated for @entity164 2 @entity6 , and (ii) whether treatment escalation is prompted by a rise in glycaemic control [haemoglobin A 1c (HbA 1c)] or @entity1017 . METHODS: A @entity6 database was used to identify all @entity1 with @entity164 2 @entity6 attending our clinic between 1 January 1990 and 31 December 2000. To facilitate further analysis, independent anonymized database resources were established. Data collected included height, weight, gender, HbA(1c), age and @entity6 treatment at each visit. RESULTS: One thousand and eighty-four @entity1 were included; after 6 months of treatment, @entity1 ' average weight had reduced by 1.0 kg (s.d. 4.6) (p < 0.001). Sixty per cent of the @entity1 had either a decrease or no change in weight, while 40% demonstrated a @entity1017 . @entity1 demonstrated more @entity353 than @entity1 . After a mean follow-up of 50 months (s.d. 25.7), 439 @entity1 (40%) who received treatment with diet alone, diet followed by @entity2449 or @entity2449 alone demonstrated a maintained weight reduction in addition to improved glycaemic control. A rise in HbA(1c) rather than @entity1017 prompted treatment change. CONCLUSIONS: This study provides evidence that @entity1017 is not a necessary consequence of the treatment of @entity164 2 @entity6 . @entity1 were more successful than @entity1 in losing weight, and diet, with or without the addition of @entity2449 , was the treatment @entity164 most usually associated with @entity353 .
